

Rx_KnowledgeBase Web App and dataset Rx_Mappy by Lend-Rx Technology

Summary

1 **RX DATA**

Therapeutics, Company Portfolio and Pipeline, Therapeutic by disease/DrugType/Biological Targets, Clinical Trials...

2 **COVERAGE**

5000+ Companies, 1500 Tickers, 20K+ Therapeutics,

3 ACCESS

WebApp Platform and Historical Point in Time Datasets

4 USE CASES


Competitive Intelligence, Company and Product, Data Enrichment


Biotech and Pharma

DATA Coverage



A.I. EXTRACTION, LINKING AND ENRICHMENT OF INFORMATION WITH HUMAN IN THE LOOP





Taxonomies, Ontology and Mapping

THERAPEUTICS TAXONOMY

One permanent Id for each therapeutics whatever its synonyms Link to additional identifier: NDC, Registration Id, Consensus Id

THERAPEUTICS TO COMPANIES MAPPING

Historical Point in time M&A, partnerships... Clean Company Name Tickerization

THERAPEUTICS MATURITY MAPPING

Historical Point in time R&D phases to Approval By diseases

THERAPEUTICS METADATA

Clean Diseases Names Biological Targets Drug types

THERAPEUTICS KPI'S

First in class compound Supplemental indication Biological Target validated

Datasets Delivery : A weekly or Daily Delivery through S3

4 Drug Metadata

The Drug Metadata dataset below provides dynamic data at the therapeutic level. for a given timestamp of release (RELEASE_DATE) and for each drug (DRUG 00), we provide vide insease targeted by the therapeutic (REEATMENT), Dates (REEATMENT_CURRENT_PHASE_S), Start date (TREATMENT_CURRENT_PHASE_START) and End date (TREATMENT_CURRENT_PHASE_END) of the disease rial for the drug. Additional drug metada such as type of drugs (DRUG_TYPE), drugs biological target (DRUG_TARGET). The file contains also Therapeutics KPEs such as: is the current treatment in as supplemental condution (NDA) for the Drug (DRUG_ATREADY_APROVED), is the Drug a First in Class for a disease (DRUG_FIRST_N_CLASS), and upcoming Catalysts and expected date. Weekly files delivered each Mooday (cf ELEASE_DATE) and FULL REFRESH of Therapeutics data meaning data the file contains all binomation updated the previous Fidary.

Column Name	Description	Format	Example
DRUG_ID	Unique identifier of the drug	long integer	10729
DRUG_NAMES	Names of the drug, Names of the drug are separeted by pipe (not available in trial version)	string, pipe separator	Keytruda
VALUE_DATE	Date of validity of the information (UTC). Information known the previous Friday (D-3) before Data Delivery at Release Day (D)	yyyy-MM-dd	2020-09-21
COMPUTATION_TIME	Date of computation of information. Convention : All information dated at VALUE_DATE are computed the next Monday (same date than delivery) starting at 7:30 UTC.	yyyy-MM-dd HH:mm:ss zzz	2020-09-24 07:30:00 UTC
RELEASE_TIME	Timestamp for the moment of data release. For now data is delivered each Monday at 12:00 UTC	yyyy-MM-dd HH:mm:ss zzz	2020-09-24 12:00:00 UTC
RELEASE_DATE	Date of data delivery (UTC). Noon UTC each	yyyy-MM-dd	2020-09-24
DRUG_CURRENT_PHASE	Drug's most advanced clinical stage, phase, nda/bla, approved	string	phase 3
DISEASE_NAME	Name of the disease within Lend-Rx Database. Convention : All disease synonyms from sources are disambiguated with Lend-Rx NLP platform.	string	Lung Cancer
DISEASE_ID	Unique identifier for the disease	long integer	460
TREATMENT_PHASE	Drug clinical stage for the disease, phase, nda/bla, approved	string	phase 3
TREATMENT_PHASE_START	VÂLUE DATE (refered a last update posted in clinical trial gov for instance) of the effective start (meaning that recuitement started) of the treatment (drug+disease) for the Therapeutic.	уууу-MM-dd	2011-03-11
TREATMENT_PHASE_END	VALUE, DATE (refered as a last update posted in clinicalital good for instance) at which drug ends treatment (drug-disease) phase. End of treatment phase can be moving to next development stage (see TREATMENT_PHASE_START) or end phase for termination and expected time for end of trial phase when date is specific to the	yyyy-MM-dd	2018-12-31
TARGET_NAMES	PETEASE DATE for Drug Amound Data is Name of the biological targets of the drug. When Therapeutics act on several targets, target name are seoarated by Pipe seoarator	string	PD-1
TARGET_ID	Unique identifier for the biological targets of the drug. When Therapeutics act on several targets, target Id are separated by Pine separator	long integer	1578
DRUG_TYPE	Name of the Drug Type of the drug: ex Monoclonal Antibody, ADC, etc	string	Monoclonal Antibody
DRUG_TYPE_ID	Unique identifier for the drug type	long integer	15
INACTIVE_TREATMENT	Is the Drug has no treatment ongoing at release date over the last 6 months	Boolean	FALSE
DRUG_ALREADY_APPROVED	Is the Drug already approved for at least one condition at release date	Boolean	TRUE
DRUG_FIRST_IN_CLASS	Is Drug with Disease and Target FIRST IN CLASS, meaning the drug has a novel biological target to address the disease and is the most advanced	Boolean	TRUE
DRUG_TARGET_APPROVED	Is the Target for the Disease bas been already approved by regulator	Boolean	TRUE
DRUG_NEXT_CATALYST_TYPE	Next expected catalyst for the Treatment; for example: Primary Completion date, PDUFA	String	PDUFA
DRUG_NEXT_CATALYST_DATE	Expected Date of the next catalyst	yyyy-MM-dd	TRUE
Copyright 2022 Lend-Ex Technology SAS.	All right reserved		www.lend-rxtech.com

- Comprehensive and Quant Friendly Dataset
- Historical Point in Time Data since 2016
- Daily update with from 30 minutes to 24 hours lag
- Historical Data for Trial
- Download DataDictionary

Web Application DashBoards content

Data vizualization tool, Data download, Report production



COMPETITIVE INTELLIGENCE

Therapeutics by Disease, Drug Targets, Drug Type Clinical Trials by Disease mapped to Press Releases Press Releases by Disease, Topics, Date Catalysts by Disease, Date

COMPANY

- Portfolio and Pipeline
- Partnerships by Therapeutics
- Active Clinical Trials mapped to Press Releases
- News classify by Topic and Sentiment
- Catalysts

THERAPEUTIC

Conditions by Phase Therapeutic metadata and KPIs Historical and Current Clinical Trials Press Releases with topic and sentiment Catalysts

Transparency of information

Reach underlying source of information through a simple click

1g :				_						
UPIXENT										
Other names : DUPIXENT / dupihumab / D REON-668 /	upixent / REGN	68 / SAR231893 / SA	R-231893 / The Die	rapeutic franchise : Dematolog estive / Infectious Diseases / Al	y / ENT/Dental / Immunolo	ogy / Respiratory / Unio	2029/21/	46		1
Company : SANOFI				g type : monoclonal antibodies				Phase 3	Phase 2	Phase
Company partner : REGENERON PHARM	ACEUTICALS	_	Tag	get : il13 / il4						
Current phase : approved (since 2017-03-2	E)									
Description. 🗸										
								a du		
								Social	Treatmen	ts
								Social	Treatmen	ts
aical miak - DIPIXENT								Social	Treatmen	ts
nical trials : DUPIXENT								Social	Treatmen	ts
nical trials : DUPIXENT								Social	Treatmen	ts
				◆ Ph	nel 🌩 Phase 2 🔶 Ph	anse 3		Social	Treatmen	its
nical trials : DUPIXENT				◆ P ⁵	ase 1 🔶 Phase 2 🌩 Ph	aase 3			Treatmen	ts
				◆ Pa	ase 1 🔶 Phase 2 🔶 Ph	asse 3	LEENTYANSA		Treatmen	its
FIGHUS	NCT012			S. CHRONOS	NCT60054	NCT03			Treatmen	ts
FIGHUS	NCT012	8223	NG NO	S., CHRONOS 19197., NCTO240., NCTO	NCT60054	NCT03	LIBERTYAFRSA		Treatmen	ts
Fransa Fungal Intection	NCT012		NG NO	5 CHRONOS 20117 MCTC240 NCTC 2101248311	NCTCODE4 RCTC Liberty AC	N2T03	LIBERTY AFROM		Treatmen	ts
FIGHUS	NCT012		NG NO	5 CHRONOS 20117 MCTC240 NCTC 2101248311	NCT60054	N2T03	LIBERTYAFRSA		Treatmen	ts
Fransa Fungal Intection	NCT012		NG NO	6 CHRONOS 19197 NOTO240 NOTO TOTHASTI 1930	NCTCODE4 RCTC Liberty AC	N2T03	LIBERTY AFROM		Treatmen	ts
Fransa Fungal Intection	NCT012		NG NO	2. CHRONOS 19997. NGT1246. ACTT 1997. SGL0-00. 1997. SGL0-00. 1907. SGL0-00. 1907. SGL0-00. 1907. SGL0-00.	NCTC0354 RCTD Ubwy ACI NCTC033450	N2T03	LIBERTY AFROM		Treatmen	ts
Fransa Fungal Intection	NCT012		NG NO	Coleconds Motreele. Motreele. Motreele. Soco Sococo Soco Soco Sococo S	NCTC0354 RCTD Ubwy ACI NCTC033450	N2T03	LIBERTY AFROM		Treatmen	ts
Fransa Fungal Intection	ACTO12		NG NO	2. CHRONOS 19997. NGT1246. ACTT 1997. SGL0-00. 1997. SGL0-00. 1907. SGL0-00. 1907. SGL0-00. 1907. SGL0-00.	NCTC0354 RCTD Ubwy ACI NCTC033450	N2T03	LIBERTY AFROM		Treatmen	ts

CLICK ON DATA OF INTEREST

		CT02260986 CONOS Trial		
	Trial Details	KPInDrug		
primary compli Time Frame : E primary endpoi Participants Wi Assessment (IC	Years	Drug approved : True Status : Completed Phase : phase 3		÷
4			- Þ	
	Т	rial Results		
	Pre	ess Release		
published_at	link RSS		seati	
2017-03-04	https://www.globenewswire.com/	news-release 2017/03/04/931605/0/en/Sanofi-and		



Sanofi and Regeneron Announce Presentation of Positive Data from Long-Term Pivotal Phase 3 CHRONOS Study of Dupixent® (dupilumab) in Moderate-to-Severe Atopic Dermatitis


March 04, 2017 10:30 ET| Source: Sanofi - Aventis Groupe Fate-


TO HAVE MORE DETAIL


AND REACH THE SOURCE OF INFORMATION

Therapeutics Dashboard overview

20K+ Therapeutics, Global coverage







THERAPEUTICS DETAIL

Live and terminated conditions

Therapeutics metadata

Therapeutics Partner

CLINICAL TRIALS


Historical and Current

Access to details and related Press Releases

THERAPEUTIC SALES & EXPECTATIONS

Companies Dashboard overview

5K+ Companies, 1.5K Tickers



phase 3
L.
deginal Target. Drog Type Therepeate Frenchine Name

CandyorDana	NCT	Theopenics		Catalyst			Place	Company	Jan resonant
		All	• T	All		~ T	А. т	AL	
201-10-27	NUTHINGS	1543		1041,1042			plane 2		2121-09-29
205-0-0	30220402800	Q24-300		1944,3542			place 2		202-09-39
205-0-0	NUMBER OF	5240		2046,35482			place 2 place 2		2023-03-23
30-0-3	30271/3888/168	02017008		1944,3542			plaw 2		2021-08-21
2041-3	NCT10348108	AE-121		TIM, PENNIT, J	NITLAN		plane 2		20147-0
3040-3	NCTREMOTE	12.144		TRAL PROVINCE	INFLETIOS		pine 1		2021-08-28
2040-3	NCTIONUUM	15.044		TRAL_COMPLETE	8		plane 1		2021-04-24
2040-21	SCTORMED	tep-204040		TRAL PROVINCY	INFLETION		ptase 2		202-0-0
2040-3	NCTIONE248	124.02		TRAL_CONFLICTO	8		ptere 2		2021-01-30
2048-29	SCENTING	04134		TRAL PROVERS	INFLITIOS		pine 2		2121-01-09
204-05-30	3020078046	Rear 10		TRAL_CONDUCTO	2		plan 2		2123-43-20
2040-0	SCIMIN'S	and the second s		TAL PROVIDE	NULTION NO.		plane 2		2214-2
20+0-0		28.46		TILL, PELLET, O	X0ABCETROS		plane 2		20-0-0
20+0-0 Free Releases		#-10 Date:	Tapa .	TEAL, PROVER, O	Indianal	76	plane 2		20-0-0
Prez Reliance		Doars		- TEAL, MORANT, C		204	place 2		20-0-0
Prez Reliance	Deg	Doars			Instant				2563
Pres Relator	Breg All w	None Y All w Y	Al		Instant	ware residence realised	a partnament at mana at principal data	en um faces fo alterna anges antimento para en suba conse de Cancilana de Lancia en la legación Paralizago e Para Para Mandresare	254-3
Free Releases	Breg All w skpa10	рания 7 Ал — У Ал —	All			Actes Language Langue	a antecanante de ressos de principal de corre		
Pres Releases	Brog All w Reserve	Disase Y All we with the second	All Relations LAPETUREDEPERTON_ADDR		Internet All • ¥ Internet Internet	acara composito composi 12.1. Port nel Deg Administr Actuale linearen Pocifie De	a antecanante de ressos de principal de corre	fer Lehrkinson Filmed en Importan Findings e Third Party Mandatonee 1966 - 1 Told of Tellumilet Orean 1 17% for the Textment of Artyst Demotitis in O	
Press Releases Dete mart server 2023-09-09	Drg All w All BGD18 DSEXAS D	Disase Y All w Y Ange Senation Ange Senation Y ODD-Temperature Ange - Disaster Y	All Read-room Larget (Jacobs Antion), Americ Clinic (Al, 7814), Millertone	• ¥	Al v Y pages	anama amegintes company 12.8. Pool nel Deg Administr Arcuto America Positiv Tar 2003/1210 (decimanos) Po	a anti-antic it coust of one of the co- station laters Despite Taylors Letter in while the DETECHNED MED News	fer Lehrkinson Filmed en Importan Findings e Third Party Mandatonee 1966 - 1 Told of Tellumilet Orean 1 17% for the Textment of Artyst Demotitis in O	lähen Ages 7 to 3
Press Releases Date and server 2023-03-00 2023-08-00 2023-08-00	Breg All w BRC275 ERC275 ERC275 ERC275	Person χ ΔΔ ω Ψ Μαρι Συκατία Μαρι Συκατία Φ Φ Ο205 - Solvates Βακατία Αμης Συκατία Φ	All Relations LATTIZEDETLATOR_ARED CLERCK_TELLINE_ARED REDITLATOR_AREDIAL	•] ¥ 04.300070-01.	Al v Y Jacob patro patro patro	actars composes compare U.S. Pool and Dog Administr Arctic Amounts Portice Te EDUCYTHE (Arctication) for Arctic Scheme Technication ()	namenatori et constata e congraf e acco estas lacos: Desgine Desgine Leite I esile lona DESECUENTE Prese cares Paulto e COLP Quales de Val- ente e 11% leggineares Here Desg	fer Lehrkännande Dannel om Segnerisen Flucinge av Thair Party Manufarsnare Offenen 1 Statie af Flucingation of Segneris (Statistica) of Segneris av Angel, Demonstria in O denter 6- oversen Angel, Demonstria	Dires Ages 2 to 3
Press Robuston Dess 2012-10-00 2012-00-00 2012-00-00 2012-00-00 2012-00-00 2012-00-00	Deg All w Beccris Datas Beccris Beccris Datas Datas	Jones Y All w W Y Ange - mession W Ange - Denotion CODD - Structure Longer - Ange -	All Reactions LATE Construction (Annual Construction (Annual) Resonances (Annual) Resonances (Annual)	•] ¥ 04.300070-01.	Al v Y para y para y para y para y	actes competes compete 2.1. Peel of Deg Administr Actes Assess Polity Re EBCLYING (Actual Po Actes Intern Technicae D Actes Intern Polity Le	n annanan a mar a' mar a' mar a ann ban Caupta Agus a ba ach ba 121100120140140 Anna ann Auto Chil Guine a b Sa ann Alfri Agusann Sha	The 2-deformed Toront on Segments Parallage or "Date Party Mandoneous Dates 17 Date of Parallaciane Orean 110% for the Demonstra of Angel Demonstra in D dates to serve Angel Demonstra generation on the PEA for the Theometer of Angel Demonstra in Adults and Christen Age	Dires Ages 2 to 3
Press Robuston Des 2023-01-02 2023-03-03 2023-04-03 2023-04-03 2023-04-03 2023-04-03 2023-04-03	Deg Arasin BECINS DEXES BECINS DEXES DEXES DEXES	Ποποι Ψ Αδα ω Ψ Αύρις Jonatins Ο Ο Αύρις Jonatins Ο Ο Αύρις Jonatins Ο Ο Η Αύρις Jonatins Ο Ο Ο Η Η Αύρις Jonatins Ο Ο Ο Η Η Αύρις Jonatins Αύρις Jonati	Al mainten Latitude and and and contactor and and height contactor and an height contactor and an contactor and and contactor and and contactor and and contac	•] ¥ 04.300070-01.	Al v Y parant parant parant parant parant parant parant	Anna company company 2.1. Port of Dag Alminist Anna America Port State ERCYTH (Artistant Anna Mana Artistant Artistant Anna Port Sa	n annanan a mar a' mar a' mar a ann ban Caupta Agus a ba ach ba 121100120140140 Anna ann Auto Chil Guine a b Sa ann Alfri Agusann Sha	In Cardinand Taol on Topolina Parling of Third Part Mandhane Cheen Third of Defaulties Cardina (Cardin for the Tomassi of Anges Downton in D Instein wave and Ange Downton galanties to a Regis Downton (The Tomas) Davids and Angese Hillings from Theorem (Instein Age 19). The Second Davids and Angese Hillings from Theorem (Instein Age) for Department From in Dense Table (Tomas) (SUE)	Dires Ages 2 to 3
Press Robuster Press 2023-01-02 2023-02 2	Deng All w Arrasti BRCS111 DRC	Dense w y All w) Y Ampl Dwares W Y Ampl Dwares W Y Ampl Dwares COD ² - Messels Mapl Dwares COD ² - Messels Common Ampl - Messels COD ² - Messels COD ² - Messels Demants Ampl - Dwares Ampl - Dwares Ampl Dwares Ampl - Dwares Ampl - Dwares Ampl - Dwares	All Indextores LATETASIONICATION, ANNO CORECK, PEAK AND ANNO INTERPORTATION, ANNO ALLAND CORECK, PEAK AND ANNO ALLAND INTERPORTATION, ANNO ALL	•] ¥ 04.300070-01.	And and a second	anata sampana sampana 12.1 Peol asi Dag Alashim Anata Jamasan Pedra Sa 2003/124 (Anata Sa Anata Jahan Jahara Jahara) Anata Jahan Palamiri Ja 3000 (2010) Anata Jahan Palamiri Ja	a constant is reaso of range to nor- date boos Complex Reports Like to such the 2010 COMO (Spice Report waves 11/15 Supplementation) and says from Report of Particular State and Participants (Spicese Spicese Spices	In Landsman Bauel on Superior Proling or Third Prov Handbarer Chines Their of Public Aller States of the International Chines Denotes in 20 International Chinese Public P	Dires Ages 2 to 3
Press Robuster Res 2023-01-02 2023-04-03 2023-04-03 2023-04-03 2023-04-03 2023-04-03 2023-04-03 2023-04-03 2023-04-03	Deg All w Astraction BERCHTS BERCHTS DARAGE BERCHTS BERCHTS	Jones W All we were sensitive and were sensesensitite and were sensitive and were sensitive and were sensese	All Industries LATTUSIONICATOR, UNIO COROCA, PEAL MEDITAL INTERNAL AND ANTONIA AND COROCA, PEAL AND ANTONIA INTERNAL AND ANTONIA INTERNAL AND ANTONIA	•] ¥ 04.300070-01.	And V	action companies companies 12.1 Peri and Dag Administra Arcido Annancio Paulito Da 1250/1118 (Arcine) Da Arcido Annancio Paulito D Arcido Annancio Paulito Di Accogn (2019 Paulito) Di Da Arcigno (2019 Paulito) Di Dana Annancio Pauli D	commente a resta vi men e fore ente han Chargen Tapane Leve anto han 2020/02/02/02 Fore anno hanto COBO Opena do Na ente 12/10/02/02/02 Open ente 12/10/2020/02/02 Open ente 12/10/2020/02/02 Opena op fore Resta of Defaulties Com en forest Quere SUD Pleased Rest		Dires Ages 2 to 3
Press Robane 2009 2020-01-02 2020-09-09 2020-09-000-000-000-000-000-000-000-000-	Breg All w All w BAGNTS BAGNTS DADAS BAGNTS DADAS BAGNTS DADAS BAGNTS BAGNTS BAGNTS BAGNTS BAGNTS BAGNTS BAGNTS BAGNTS BAGNTS BAGNTS BAGNTS	Νωτ γ Τρισμιστική	А таклона Слана, алека Слана, архикализация Банеталова, анинова, Банеталова, анинова, Салока, така, каланова, Салока, така, каланова, Салока, така, каланова, Салока, така, каланова, Салока, така, каланова, Банеталова, така, Банеталова, анинова, Банеталова, така, Банеталова, така, Банеталова, Банет	•] ¥ 04.300070-01.	ANT Y	autora composito company UE Parti and Party Ankonen Arcitik Similaren Partis for 18/02/1988 (chicasanti fi Arcitik Similaren Partis Ca Bille Arcitig Similar Similaren Fi Bille Arcitig Similar Similaren Billeren Stempetero Annoren Billeren Annoren Partes 1 Similar Annoren Partes 1 Similar Annoren Partes 1	a samaana a maa a maa a maa a ana loon Couglan Rayma Law J aho loon Couglan Rayma Law J aho loon Couglan Rayma Law J aho Ray and Palana Sama Sama ay Teo Ray and Palana Sama ahong pulawa Ray and Palana Sa ahong pulawa Ray ang Palana Sa ahong pulawa		Dires Ages 2 to 3
Press Robases Press Robases 2023-01-02 2023-01-02 2023-04-02 2033-04-02 2033-04-02 2033-04-02 2033-04-02 2033-04-02 2033-04-02 2033-04-02 2033-04-02	Img All u Auszill 1 Status 1	Νωτ γ Τρισμιστική	Al macrossi Later 2015 2.000 , Janes 2015 2.000 , Janes 2.000 , Janes 2015 2.000 , Janes 2.000 ,	•] ¥ 04.300070-01.	Adam M • Y part part part part part part part part	autor composer company VII Prot of Day, Ankoren Arcicle Strategies and Arcicle Strategies 12/02/19/14 (Arcicle Strategies), Arc Arcicle Strategies Technical Strategies Arcicle Strategies Technical Strategies Arcicle Strategies Technical Strategies Roman Amorece Protect Str Report Printprint Company Technical Strategies Amoreces Prints Strategies	a samulant process of receipt of servi- ness home company. Represent from the service of the samulation of the samulation of the samulation of the samulation of the service of the samulation o		illen Ages 2 to 1 4 Years and Other a Transmost of Mail to
Press Robuster Des Des Des Des Des Des Des Des Des Des	Img All w Autorit autorit Billititi autorit	Imm γ Δ μ μμ μμ μμ <t< td=""><td>Al macrossi Later 2015 2.000 , Janes 2015 2.000 , Janes 2.000 , Janes 2015 2.000 , Janes 2.000 ,</td><td> Ψ Ψ №</td><td></td><td>autora compositore company sectore compositore company devide Automateria devide Automateria devide Automateria devide Automateria devide Automateria devide Automateria Biolice Automateria Biolice Automateria devide Automateria Biolice Automateria devide Automateria devide</td><td>contrasting in some of tensor of tensor time have transported by the source of ten- sors have transported by the source of ten- terior tensors in the source of the source of ten- terior tensors in the source of the source of ten- terior tensors in the source of the source of ten- terior tensors in the source of tensors in the source of tensors in the source of tensors in the source of tensors in the source of tensors in the source of tensors in the source of tensors in the lensors in tensors in the source of tensors in the lensors in tensors in the source of tensors in the source of tensors in the lensors in tensors in the source of tenso</td><td></td><td>idens Ages 7 to 1 ef Yeans and Online in Theorem of Albit to of general least of Albit to</td></t<>	Al macrossi Later 2015 2.000 , Janes 2015 2.000 , Janes 2.000 , Janes 2015 2.000 , Janes 2.000 ,	 Ψ Ψ №		autora compositore company sectore compositore company devide Automateria devide Automateria devide Automateria devide Automateria devide Automateria devide Automateria Biolice Automateria Biolice Automateria devide Automateria Biolice Automateria devide	contrasting in some of tensor of tensor time have transported by the source of ten- sors have transported by the source of ten- terior tensors in the source of the source of ten- terior tensors in the source of the source of ten- terior tensors in the source of the source of ten- terior tensors in the source of tensors in the source of tensors in the source of tensors in the source of tensors in the source of tensors in the source of tensors in the source of tensors in the lensors in tensors in the source of tensors in the lensors in tensors in the source of tensors in the source of tensors in the lensors in tensors in the source of tenso		idens Ages 7 to 1 ef Yeans and Online in Theorem of Albit to of general least of Albit to
Press Robuster Rose 2023-04-02 20	Img All w BGUTS Debta Debta w	Νου γ β Δ	А маклон Маркон Сласа, ула, застоя напоза со ученом. Папоза ученом. Сласа, уза, на со ученом.	 Ψ Ψ №		nation composition composition 12.12 Proof and Deep Advances Advantion Amazaman Proof to B 2020/2028 (coloramics Proof to A Arranto Instances Proof to A Arranto Instances Proof to A Arranto Instances Proof to A Reports Theory and A Reports Theory and A Reports Proof to A Reports Proof to A Report Amazaman Proof to A Instance Amazaman Proof to A Report A Report A Report A Report A Report A Report A Report A Report A Report	contraction is create or strong or loca- tion have Contraction of the		idens Ages 7 to 1 ef Yeans and Online in Theorem of Albit to of general least of Albit to

FILTERING

Search companies by Conditions/Technology/Maturity


PORTFOLIO AND PIPELINE

Visualize in graph or tabs Download data **NEWS&CATALYSTS**

News Classified by Topics Upcoming Company Catalysts

Competitive Intelligence Dashboard overview

1.5K diseases, 1K+ Therapeutic Targets, circa 30 Technologies



THERAPEUTIC COMPETITION

Current and Upcoming By Timing, By Revenue

CLINICAL TRIALS

Ongoing by Phase Reach details for Data transparency

NEWS&CATALYSTS

News Classifier by Topics/Phase/Date Upcoming Events: Trial Results/Registration Milestones/Congress



You've heard from us.

we want to hear from you.

- **(**) +336.5089.9073
- © contact@lend-rxtech.com
- www.lend-rxtech.com